HIGHLIGHTS
- who: Correction et al. from the Institute for Systems Biology (ISB), United StatesDepartment of Gynecology, Harbin Medical University Cancer Hospital, Harbin, China, Department have published the research work: Corrigendum: A potential indicator ARRDC2 has feasibility to evaluate prognosis and immune microenvironment in ovarian cancer, in the Journal: (JOURNAL) of 24/08/2022
SUMMARY
Arrestin domain containing 2, biomarker, immunity, prognosis, ovarian cancer A Corrigendum on A potential indicator ARRDC2 has feasibility to evaluate prognosis and immune microenvironment in ovarian cancer by Zhang M, Liu Y, Liu Y, Hou S, Li H, Ma Y . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.